Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Thursday's Bonus Content Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorAuthored by Jeffrey Neal Johnson. First Published: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of approximately $245 per share, creating a divergence that has caught Wall Street's attention. This rally runs counter to the common perception of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. That gain suggests institutional money is rotating out of riskier assets and placing a premium on stability, consistent cash flow, and solid execution. For investors watching the ticker today, Feb. 24, 2026, it's important to note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely decline by the amount of the upcoming dividend payment—$1.30 per share—as a mechanical adjustment. That drop is not a reflection of business performance or a company sell-off; for income-focused investors, it often represents an attractive entry opportunity rather than a sell signal. 64 Years of Unbroken Growth The primary argument for holding Johnson & Johnson through turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings—companies that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes, and geopolitical conflicts. That consistency is a rare commodity in a market focused on speculative growth. Currently, the stock yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist elsewhere—such as in bonds or riskier sectors—the appeal here is the blend of growth and safety. The dividend is backed by a large liquidity cushion: management projects free cash flow of roughly $21 billion in 2026. That level of cash generation helps ensure the company can continue paying shareholders, fund research, and manage legal expenses without heavy borrowing. For risk-averse investors, one of the most compelling metrics is the stock's Beta. Beta measures how much a stock moves compared to the overall market (S&P 500). A Beta of 1.0 indicates movement in step with the market; Johnson & Johnson's Beta is just 0.35. In other words, the stock is historically about 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio acts as a mathematical shock absorber, dampening overall volatility while still providing equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe, dividend-paying stocks is that they cannot grow. Johnson & Johnson is disproving that with a strategic pivot that is paying off. Management has issued strong guidance for 2026, projecting full-year revenue to exceed the $100 billion threshold for the first time in the company's history. Alongside that milestone, the company anticipates adjusted earnings per share (EPS) of about $11.53. This growth is driven by a reinvention of its pharmaceutical division, now branded as Innovative Medicine. For years, investors worried about a patent cliff for Stelara, a blockbuster immunology drug that lost exclusivity in 2025. Typically, when a top drug faces generic competition, revenue can collapse. However, J&J has offset that decline with the rapid ascent of new blockbusters. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse generates roughly $14 billion in annual sales and has cemented the company's leadership in treating multiple myeloma, becoming a foundational therapy worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently released strong three-year data on remission rates for ulcerative colitis. That clinical success is critical for retaining market share in the competitive immunology space as older drugs fade.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech division, which has shifted its focus to high-growth, higher-margin technologies. A prime example is the integration of Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave uses intravascular lithotripsy (IVL) technology—sonic pressure waves that safely break up calcified plaque in arteries, similar to treatments for kidney stones. This approach is a notable improvement over traditional angioplasty balloons. By owning this technology, Johnson & Johnson has added a high-growth asset that complements its heart device and surgical businesses. The company is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intention to compete directly in the expanding soft-tissue robotics market. These high-tech devices typically carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind that goes beyond commodity surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the company's portfolio. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a larger divestiture. Divesting the orthopedics unit is a classic example of addition by subtraction. Orthopedics is a mature, lower-growth business compared with the booming fields of oncology and cardiovascular devices. Shedding this slower unit would improve overall revenue growth and profit margins. A sale would also generate a significant lump-sum payment—potentially billions—providing capital for acquisitions, R&D, or share buybacks. Addressing legal risks is essential for a balanced view of Johnson & Johnson. The company continues to face litigation over talc products, including a recent $1.5 billion verdict, and a commercial lawsuit from Bayer concerning marketing claims for prostate cancer drugs has added noise to the news cycle. Still, the stock's recent rally suggests the market is looking past headline risk. The prevailing view among bulls is that Johnson & Johnson has the financial depth to manage these liabilities without disrupting its business. With over $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company has a financial fortress capable of absorbing legal settlements. That strength keeps legal battles as balance-sheet items rather than existential threats to the dividend or operations. Capital Preservation With Upside Johnson & Johnson has successfully evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. By spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, management is streamlining operations to concentrate on higher-growth opportunities in pharmaceuticals and medical technology. While the stock is no longer a bargain, trading near all-time highs, it offers a valuable mix of capital preservation and growth that can be hard to find elsewhere. The combination of a 64-year dividend growth streak, a remarkably low volatility profile, and a clear path to $100 billion in revenue makes J&J a compelling option for 2026. For investors tired of the unpredictability in technology, Johnson & Johnson demonstrates that, in the current market environment, boring can be both beautiful and profitable.
| 
